Clinical Trials Logo

Plaque Psoriasis clinical trials

View clinical trials related to Plaque Psoriasis.

Filter by:

NCT ID: NCT02412644 Completed - Plaque Psoriasis Clinical Trials

Apremilast 30mg Bid With Narrowband UVB in the Treatment of Plaque Psoriasis

Start date: May 28, 2015
Phase: Phase 4
Study type: Interventional

12 weeks open label with Otezla® and NUVB, followed by 6 month double blind Otezla® (apremilast) or placebo to subjects who obtain PASI 75 at week 12 of phototherapy

NCT ID: NCT02409667 Completed - Plaque Psoriasis Clinical Trials

Plaque Psoriasis Efficacy and Safety With Secukinumab

OPTIMISE
Start date: May 7, 2015
Phase: Phase 3
Study type: Interventional

To demonstrate in the patient pool of PASI 90 responders at Week 24 that secukinumab 300 mg s.c. when administered at a longer dosing interval is non-inferior to secukinumab 300 mg s.c. every 4 weeks treatment with respect to maintaining a PASI 90 response rate at Week 52.

NCT ID: NCT02368210 Completed - Plaque Psoriasis Clinical Trials

A Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis (Study 306)

Start date: January 2015
Phase: Phase 3
Study type: Interventional

This Phase 3 study (Study 306) has been designed to determine and compare the efficacy and safety of 122-0551 Foam and Vehicle Foam applied twice daily for two weeks in subjects with plaque psoriasis.

NCT ID: NCT02367911 Completed - Plaque Psoriasis Clinical Trials

A Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis

Start date: January 2015
Phase: Phase 3
Study type: Interventional

This Phase 3 study has been designed to determine and compare the efficacy and safety of 122-0551 Foam and Vehicle Foam applied twice daily for two weeks in subjects with plaque psoriasis.

NCT ID: NCT02346240 Completed - Psoriasis Clinical Trials

Efficacy and Safety Study of Certolizumab Pegol (CZP) Versus Active Comparator and Placebo in Subjects With Plaque Psoriasis (PSO)

CIMPACT
Start date: February 11, 2015
Phase: Phase 3
Study type: Interventional

The purpose of this study is to investigate the efficacy and safety of two dose levels of certolizumab pegol compared to active comparator and placebo in adults with moderate to severe chronic plaque psoriasis.

NCT ID: NCT02340169 Completed - Plaque Psoriasis Clinical Trials

Adrenal Suppression and Pharmacokinetics of Topicort® Spray, 0.25% in Pediatric Patients With Plaque Psoriasis

Start date: January 23, 2015
Phase: Phase 4
Study type: Interventional

The objective of this study is to evaluate the potential of Topicort® (desoximetasone) Topical Spray, 0.25% to suppress hypothalmic pituitary adrenal axis function. The secondary objectives are to evaluate the efficacy parameters, pharmacokinetics and adverse event profile.

NCT ID: NCT02326298 Completed - Psoriasis Clinical Trials

An Efficacy and Safety Study of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO)

CIMPASI-1
Start date: December 16, 2014
Phase: Phase 3
Study type: Interventional

The purpose of this study is to investigate the efficacy and safety of two dose levels of certolizumab pegol in adults with moderate to severe chronic plaque psoriasis when administered every 2 weeks.

NCT ID: NCT02326272 Completed - Psoriasis Clinical Trials

A Study to Evaluate the Efficacy and Safety of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO)

CIMPASI-2
Start date: December 15, 2014
Phase: Phase 3
Study type: Interventional

The purpose of this study is to investigate the efficacy and safety of two dose levels of certolizumab pegol in adults with moderate to severe chronic plaque psoriasis.

NCT ID: NCT02310750 Completed - Plaque Psoriasis Clinical Trials

A Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06700841, With Bioavailability/Food Effect Investigation

Start date: November 2014
Phase: Phase 1
Study type: Interventional

The main purpose of the study is to determine if PF-06700841 is safe and well tolerated when administered to humans. A secondary purpose is to assess what the body does to PF-06700841 and to assess what PF-06700841 does to the body when given as single and multiple doses. The pharmacokinetic properties of different forms of PF-06700841 may be studied (tablet and solution/suspension forms).

NCT ID: NCT02274792 Completed - Plaque Psoriasis Clinical Trials

Study to Assess the Immunogenicity and Safety of Etanercept Produced in Plaque Psoriasis

Start date: January 2015
Phase: Phase 4
Study type: Interventional

The purpose of this study is to learn more about the immune response to etanercept in patients with plaque psoriasis.